The cathepsin B inhibitor, z-FA-FMK, inhibits human T cell proliferation in vitro and modulates host response to pneumococcal infection in vivo

Journal of Immunology

Volumn 177, Issue 6, 2006, Pages 3827-3836

  Lawrence, Clare P ^a   Kadioglu, Aras ^a   Yang, Ai Li ^a   Coward, William R ^a   Chow, Sek C ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLPHENYLALANYLALANYL FLUOROMETHYL KETONE; CASPASE 3; CASPASE 8; CATHEPSIN B; CATHEPSIN B INHIBITOR; CD69 ANTIGEN; ENZYME INHIBITOR; FAS ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; LYMPHOCYTE ANTIGEN RECEPTOR; MITOGENIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; BLOOD; BRONCHOPNEUMONIA; CELL CYCLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LUNG; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; T LYMPHOBLAST; T LYMPHOCYTE ACTIVATION;

EID: 33748503609     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.6.3827     Document Type: Article

References (48)

1. Rasnick, D. 1985. Synthesis of peptide fluoromethyl ketones and the inhibition of human cathepsin B. Anal. Biochem. 149: 461-465.
2. Ahmed, N. K., L. A. Martin, L. M. Watts, J. Palmer, L. Thornburg, J. Prior, and R. E. Esser. 1992. Peptidyl fluoromethyl ketones as inhibitors of cathepsin B: implication for treatment of rheumatoid arthritis. Biochem. Pharmacol. 44: 1201-1207.
3. Tanaka, Y., R. Tanaka, T. Kawabata, Y. Noguchi, and M. Himeno. 2000. Lysosomal cysteine protease, cathepsin B, is targeted to lysosomes by the mannose 6-phosphate-independent pathway in rat hepatocytes: site-specific phosphorylation in oligosaccharides of the proregion. J. Biochem. 128: 39-48.
4. Lenarcic, B., D. Gabrijelcic, B. Rozman, M. Drobnic-Kosorok, and V. Turk. 1988. Human cathepsin B and cysteine proteinase inhibitors (CPIs) in inflammatory and metabolic joint diseases. Biol. Chem. Hoppe Seyler 369: 257-261.
5. Gabrijelcic, D., A. Annan-Prah, B. Rodic, B. Rozman, V. Cotic, and V. Turk. 1990. Determination of cathepsins B and H in sera and synovial fluids of patients with different joint diseases. J. Clin. Chem. Clin. Biochem. 28: 149-153.
6. Etherington, D. J., M. A. Taylor, and B. Henderson. 1988. Elevation of cathepsin L levels in the synovial lining of rabbits with antigen-induced arthritis. Br. J. Exp. Pathol. 69: 281-289.
7. Van Noorden, C. J., and I. M. Vogels. 1986. Enzyme histochemical reactions in unfixed and undecalcified cryostat sections of mouse knee joints with special reference to arthritic lesions. Histochemistry 86: 127-133.
8. Van Noorden, C. J., R. E. Smith, and D. Rasnick. 1988. Cysteine proteinase activity in arthritic rat knee joints and the effects of a selective systemic inhibitor, Z-Phe-AlaCH2F. J. Rheumatol. 15: 1525-1535.
9. Esser, R. E., R. A. Angelo, M. D. Murphey, L. M. Watts, L. P. Thornburg, J. T. Palmer, J. W. Talhouk, and R. E. Smith. 1994. Cysteine proteinase inhibitors decrease articular cartilage and bone destruction in chronic inflammatory arthritis. Arthritis Rheum. 37: 236-247.
10. Schotte, P., R. Schauvliege, S. Janssens, and R. Beyaert. 2001. The cathepsin B inhibitor z-FA.fmk inhibits cytokine production in macrophages stimulated by lipopolysaccharide. J. Biol. Chem. 276: 21153-21157.
11. Lopez-Hernandez, F. J., M. A. Ortiz, Y. Bayon, and F. J. Piedrafita. 2003. Z-FA-fmk inhibits effector caspases but not initiator caspases 8 and 10, and demonstrates that novel anticancer retinoid-related molecules induce apoptosis via the intrinsic pathway. Mol. Cancer Ther. 2: 255-263.
12. Falk, M., S. Ussat, N. Reiling, D. Wesch, D. Kabelitz, and S. Adam-Klages. 2004. Caspase inhibition blocks human T cell proliferation by suppressing appropriate regulation of IL-2, CD25, and cell cycle-associated proteins. J. Immunol. 173: 5077-5085.
13. Chun, H. J., L. Zheng, M. Ahmad, J. Wang, C. K. Speirs, R. M. Siegel, J. K. Dale, J. Puck, J. Davis, C. G. Hall, et al. 2002. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 419: 395-399.
14. Alam, A., L. Y. Cohen, S. Aouad, and R.-P. Sekaly. 1999. Early activation of caspases during T lymphocyte stimulation results in selective substrate cleavage in nonapoptotic cells 1332. J. Exp. Med. 190: 1879-1890.
15. Kennedy, N. J., T. Kataoka, J. Tschopp, and R. C. Budd. 1999. Caspase activation is required for T cell proliferation. J. Exp. Med. 190: 1891-1896.
16. Salmena, L., B. Lemmers, A. Hakem, E. Matysiak-Zablocki, K. Murakami, P. Y. Au, D. M. Berry, L. Tamblyn, A. Shehabeldin, E. Migon, et al. 2003. Essential role for caspase 8 in T-cell homeostasis and T-cell-mediated immunity. Genes Dev. 17: 883-895.
17. Moreland, L. W., and J. R. O'Dell. 2002. Glucocorticoids and rheumatoid arthritis: back to the future? Arthritis Rheum. 46: 2553-2563.
18. Karanikolas, G., D. Charalambopoulos, A. Andrianakos, C. Antoniades, and N. Katsilambros. 2006. Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis. J. Rheumatol. 33: 486-489.
19. Gremese, E., and G. F. Ferraccioli. 2004. Benefit/risk of cyclosporine in rheumatoid arthritis. Clin. Exp. Rheumatol. 22: S101-107.
20. Kadioglu, A., W. Coward, M. J. Colston, C. R. Hewitt, and P. W. Andrew. 2004. CD4-T-lymphocyte interactions with pneumolysin and pneumococci suggest a crucial protective role in the host response to pneumococcal infection. Infect. Immun. 72: 2689-2697.
21. Johnson, V. L., S. C. Ko, T. H. Holmstrom, J. E. Eriksson, and S. C. Chow. 2000. Effector caspases are dispensable for the early nuclear morphological changes during chemical-induced apoptosis. J. Cell Sci. 113 (Pt 17): 2941-2953.
22. Lyons, A. B., and C. R. Parish. 1994. Determination of lymphocyte division by flow cytometry. J. Immunol. Methods 171: 131-137.
23. Su, H., N. Bidere, L. Zheng, A. Cubre, K. Sakai, J. Dale, L. Salmena, R. Hakem, S. Straus, and M. Lenardo. 2005. Requirement for caspase-8 in NF-κB activation by antigen receptor. Science 307: 1465-1468.
24. Kadioglu, A., N. A. Gingles, K. Orattan, A. Kerr, T. J. Mitchell, and P. W. Andrew. 2000. Host cellular immune response to pneumococcal lung infection in mice. Infect. Immun. 68: 492-501.
25. Nelson, B. H. 2004. IL-2, regulatory T cells, and tolerance. J. Immunol. 172: 3983-3988.
26. Risso, A., D. Smilovich, M. C. Capra, I. Baldissarro, G. Yan, A. Bargellesi, and M. E. Cosulich. 1991. CD69 in resting and activated T lymphocytes: its association with a GTP binding protein and biochemical requirements for its expression. J. Immunol. 146: 4105-4114.
27. Mortellaro, A., S. Songia, P. Gnocchi, M. Ferrari, C. Fornasiero, R. D'Alessio, A. Isetta, F. Colotta, and J. Golay. 1999. New immunosuppressive drug PNU156804 blocks IL-2-dependent proliferation and NF-κB and AP-1 activation. J. Immunol. 162: 7102-7109.
28. Kischkel, F. C., S. Hellbardt, I. Behrmann, M. Germer, M. Pawlita, P. H. Krammer, and M. E. Peter. 1995. Cytotoxicity-dependent apo-1 (fas/cd95)-associated proteins form a death-inducing signaling complex (disc) with the receptor. EMBO J. 14: 5579-5588.
29. Tak, P. P., and G. S. Firestein. 2001. NF-κB a key role in inflammatory diseases. J. Clin. Invest. 107: 7-11.
30. Grilli, M., J. J. Chiu, and M. J. Lenardo. 1993. NF-κB and Rel: participants in a multiform transcriptional regulatory system. Int. Rev. Cytol. 143: 1-62.
31. Li, C.-C. H., R.-M. Dai, E. Chen, and D. L. Longo. 1994. Phosphorylation of NF-KB1-p50 is involved in NF-kB activation and stable DNA binding. J. Biol. Chem. 269: 30089-30092.
32. Palombella, V. L., O. J. Rando, A. L. Goldberg, and T. Maniatis. 1994. The ubiquitin-proteosome pathway is required for processing the NF-kB1 precursor protein and the activation of NF-kB. Cell 78: 773-785.
33. McColl, K. S., H. He, H. Zhong, C. M. Whitacre, N. A. Berger, and C. W. Distelhorst. 1998. Apoptosis induction by the glucocorticoid hormone dexamethasone and the calcium-ATPase inhibitor thapsigargin involves Bcl-2 regulated caspase activation. Mol. Cell Endocrinol. 139: 229-238.
34. Hotchkiss, R. S., K. W. Tinsley, P. E. Swanson, K. C. Chang, J. P. Cobb, T. G. Buchman, S. J. Korsmeyer, and I. E. Karl. 1999. Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc. Natl. Acad. Sci. USA 96: 14541-14546.
35. Sarin, A., M. L. Wu, and P. A. Henkart. 1996. Different interleukin-1 β converting enzyme (ICE) family protease requirements for the apoptotic death of T lymphocytes triggered by diverse stimuli. J. Exp. Med. 184: 2445-2450.
36. Stennicke, H. R., J. M. Jurgensmeier, H. Shin, Q. Deveraux, B. B. Wolf, X. Yang, Q. Zhou, H. M. Ellerby, L. M. Ellerby, D. Bredesen, et al. 1998. Pro-caspase-3 is a major physiologie target of caspase-8. J. Biol. Chem. 273: 27084-27090.
37. Martin, S. J., G. P. Amarante-Mendes, L. Shi, T. H. Chuang, C. A. Casiano, G. A. O'Brien, P. Fitzgerald, E. M. Tan, G. M. Bokoch, A. H. Greenberg, and D. R. Green. 1996. The cytotoxic cell protease granzyme B initiates apoptosis in a cell-free system by proteolytic processing and activation of the ICE/CED-3 family protease, CPP32, via a novel two-step mechanism. EMBO J. 15: 2407-2416.
38. Atkinson, E. A., M. Barry, A. J. Darmon, I. Shostak, P. C. Turner, R. W. Moyer, and R. C. Bleackley. 1998. Cytotoxic T lymphocyte-assisted suicide: caspase 3 activation is primarily the result of the direct action of granzyme B. J. Biol. Chem. 273: 21262-21266.
39. Browne, K. A., E. Blink, V. R. Sutton, C. J. Froelich, D. A. Jans, and J. A. Trapani. 1999. Cytosolic delivery of granzyme B by bacterial toxins: evidence that endosomal disruption, in addition to transmembrane pore formation, is an important function of perform. Mol. Cell Biol. 19: 8604-8615.
40. Trapani, J. A., D. A. Jans, P. J. Jans, M. J. Smyth, K. A. Browne, and V. R. Sutton. 1998. Efficient nuclear targeting of granzyme B and the nuclear consequences of apoptosis induced by granzyme B and perform are caspase-dependent, but cell death is caspase-independent. J. Biol. Chem. 273: 27934-27938.
41. Guicciardi, M. E., J. Deussing, H. Miyoshi, S. F. Bronk, P. A. Svingen, C. Peters, S. H. Kaufmann, and G. J. Gores. 2000. Cathepsin B contributes to TNF-α-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J. Clin. Invest. 106: 1127-1137.
42. Foghsgaard, L., D. Wissing, D. Mauch, U. Lademann, L. Bastholm, M. Boes, F. Elling, M. Leist, and M. Jaattela. 2001. Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. J. Cell Biol. 153: 999-1010.
43. Schotte, P., W. Van Criekinge, M. Van de Craen, G. Van Loo, M. Desmedt, J. Grooten, M. Cornelissen, L. De Ridder, J. Vandekerckhove, W. Fiers, et al. 1998. Cathepsin B-mediated activation of the proinflammatory caspase-11. Biochem. Biophys. Res. Commun. 251: 379-387.
44. Schotte, P., W. Declercq, S. Van Huffel, P. Vandenabeele, and R. Beyaert. 1999. Non-specific effects of methyl ketone peptide inhibitors of caspases. FEBS Lett. 442: 117-121.
45. Chen, L., L. Smith, Z. Wang, and J. B. Smith. 2003. Preservation of caspase-3 subunits from degradation contributes to apoptosis evoked by lactacystin: any single lysine or lysine pair of the small subunit is sufficient for ubiquitination. Mol. Pharmacol. 64: 334-345.
46. Engel, J. C., P. S. Doyle, I. Hsieh, and J. H. McKerrow. 1998. Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J. Exp. Med. 188: 725-734.
47. Tarleton, R. L. 1990. Depletion of CD8+ T cells increases susceptibility and reverses vaccine-induced immunity in mice infected with Trypanosoma cruzi. J. Immunol. 144: 717-724.
48. Tarleton, R. L., B. H. Koller, A. Latour, and M. Postan. 1992. Susceptibility of β2-microglobulin-deficient mice to Trypanosoma cruzi infection. Nature 356: 338-340.